The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia
Open Access
- 21 July 2006
- Vol. 107 (5) , 1023-1033
- https://doi.org/10.1002/cncr.22094
Abstract
BACKGROUND. Infections are a major factor in the clinical course of chronic lymphocytic leukemia (CLL) and account for 30% to 50% of all deaths. The pathogenesis of infections in CLL is related to hypo-γ-globulinemia, T-cell immune dysfunction, and the immunosuppressive effect of treatment. METHODS. The authors retrospectively assessed the correlations between new prognostic markers and types of infections encountered, the time taken to develop these infections, and infection-related mortality in 280 unselected patients with CLL. RESULTS. One hundred patients (36%) had at least 1 major infection (median, 2 major infections; range, 1–8 major infections) over a median follow-up of 67 months. Infections were the most common cause of death, accounting for 51% of all fatalities. Older age (P = .007), clinical Stage B or C disease (P < .001), unmutated immunoglobulin (Ig)VH gene status (P < .001), genetic abnormalities (P < .001), positive CD38 status (P < .001), and type of initial therapy were associated with a significantly shorter time to first infection. Equally, patient age (P < .001), disease stage (P < .001), CD38 expression (P < .001), IgVH mutation status (P < .001), and genetic abnormalities (P = .003) had a significant impact on infection-related mortality. CONCLUSIONS. Clinical stage at diagnosis, IgVH mutation status, and initial therapy were possible predictors of severe infections in patients with CLL. The current results may help to identify which patients with CLL are at particularly high risk of developing serious infections and, thus, should be considered for Ig or antibiotic prophylaxis. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 37 references indexed in Scilit:
- Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLLBlood, 2005
- Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged SurvivalJournal of Clinical Oncology, 2005
- Common Polymorphism G(-248)A in the Promoter Region of the bax Gene Results in Significantly Shorter Survival in Patients With Chronic Lymphocytic Leukemia Once Treatment Is InitiatedJournal of Clinical Oncology, 2005
- Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLLBlood, 2004
- Relationship between p53 dysfunction, CD38 expression, andIgVH mutation in chronic lymphocytic leukemiaBlood, 2002
- Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphomaCancer, 2002
- Infections in Chronic Lymphocytic Leukemia: Risk Factors, and Impact on Survival, and TreatmentLeukemia & Lymphoma, 1994
- Infections and serum IgG levels in patients with chronic lymphocytic leukemiaEuropean Journal of Haematology, 1992
- Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1988
- Serum immunoglobulins in B-chronic lymphocytic leukemia.Natural history and prognostic significanceCancer, 1988